SPECTROPHOTOMETRIC DETERMINATION OF 1-[7-(2- HYDROXYETHYL-1)-3-METHYLXANTHINE-8-YL]PIPERAZINE CHLORIDE
DOI:
https://doi.org/10.11603/2312-0967.2018.2.9011Keywords:
1-[7-(2-hydroxyethyl-1)-3-methylxanthine-8-yl]piperazine chloride, quantitative determination, UV spectrophotometry, validation.Abstract
The aim of the work. To develop and validate the UV spectrophotometric procedure for the quantitative determination of 1-[7-(2-hydroxyethyl-1)-3-methylxanthine-8-yl]piperazine chloride.
Materials and Methods. The study object was the substance of 1-[7-(2-hydroxyethyl-1)-3-methylxanthine-8-yl]piperazine chloride. Distilled water used as the solvent.
Analytical equipment: spectrophotometer Specord 200, electronic balance AVT-120-5DM, measuring glassware of class A.
Results and Discussion. The absorption band that observed at 260–320 nm with an absorption maximum at 289 nm was chosen to develop the quantitative determination method. According to SPU, the developed method was validated by the standard method for such validation characteristics as linearity, range of application, precision, accuracy and robustness. The calculated numerical values of linear dependence indicate that the method is linear throughout the selected concentration range (73–126 %). Precision was determined at the level of repeatability. It was found that the one-sided interval of a single value does not exceed the maximum permissible uncertainty of the analysis, so this method is accurate. It was proved that the absorption of the analyzed solutions remains stable for at least 1 hour. The predicted total uncertainty of the results for the quantitative determination method, which does not exceed its critical value, was also calculated. Thus, the method will give correct results in other laboratories.
Conclusion. The UV spectrophotometric procedure for the quantitative determination of 1-[7-(2-hydroxyethyl-1)-3-methylxanthine-8-yl]piperazine chloride was developed and validated.References
Mashkovskiy MD. Medical supplies. [Лекарственные средства] 16th ed. Moscow: OOO “Izdatelstvo Novaya volna”; 2012. Russian.
Luo Y, Müller CE. Preperation, properties, reactions, and adenisine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acids prodrugs with peroral bioavailability. J Med Chem. 2004;47(10):1031-43.
Gebert U, Defossa E, Khaynnel U, Rudolfi K, Groum JJ, inventors; Hoechst AG, assignee. Derivatives of xanthine with terminal aminated alkynol side chains and medicinal agent. RU 2204561 (Patent) 2003 May 20. Russian.
Baraldi PG, Borea PA, inventors; King Pharmaceuticals Research and Development Inc, assignee. 8-Heteroaryl xanthine adenosine A2B receptor antagonists. US 2003/0207879 A1 (Patent) 2003 Nov 06.
Jia Yu, Ma Yu, Cai D, inventors; Univ liaoning medical, assignee. 8-Pyrazole substituted xanthine A2B adenosine receptor antagonist and synthesis method and application thereof. CN 102532137 (Patent) 2012 Jul 04.
Maddocka HL, Gardnera NM, Khandoudib N, Brilb A, Broadleya KJ. Protection from myocardial stunning by ischaemia and hypoxia with the adenosine A3 receptor agonist, IB-MECA. Eur J Pharmacol. 2003;477(3):235-45.
Kamilov FKh, Timirkhanova GA, Samorodova AI, Khaliullin FA, Murataev DZ. [The effect of new salts of 3-methyl-1-ethylxanthine on the hemostasis system]. Modern problems of science and education. [Internet]. 2012 Dec [cited 2018 Apr 09]; 6:1-6. Available from: http://www.science-education.ru/ru/article/view?id=7873. Russian.
Kamilov FKh, Timirkhanova GA, Samorodova AI, Murataev DZ, Khaliullin FA. The search for active compounds among the derivatives of 2-[3-methyl-1-ethyl-7-(dioxothietanyl-3)xanthinyl-8-thio]acetic acid, affecting the hemostasis system. Fundam. res. 2011;9:254-6.
Kamilov FKh, Timirkhanova GA, Samorodov AV, Gubaeva RA, Akhmerova AZ, Khaliullin FA. [Search for compounds influencing the hemostasis system among derivatives of (3-methylxanthinyl-8-thio)acetic acid salts containing thietanic cycle]. Modern problems of science and education. [Internet]. 2011 Nov [cited 2018 Apr 09]; 6: 1-6. Available from: http://www.science-education.ru/ru/article/view?id=4977. Russian.
Bilggic M, inventor; Bilggic M, applicant. Pharmaceutical composition comprising N-acetylcysteine and a xanthine. WO 2011/146031 A1 (Patent) 2011 Nov 24.
Hayallah AM, Isper SA, Al-Okosh AS. Design and synthesis of some new theophylline linked amides and schiff’s bases as bronchodilatros and anti-inflammatory agents. Int Res J Pharm Pharmacol. 2012;2(12):323-36.
Dunter PW, Foley LH, Huby NJS, Pietranico-Cole SL, Yun W, inventors; Hoffmann-La Roche Inc, assignee. Sulfonamide substitued xanthine derivatives. US 20040014766 A1 (Patent) 2004 Jan 22.
Himmelsbach F, Mark M, Eckhardt M, Langkopf E, Maier R, Lotz RRH, inventors; Boehringer Ingelheim Pharma GmbH and Co KG, assignee. Xanthine derivatives, the preparation thereof and as pharmaceutical compositions. US 2013/0165428 A1 (Patent) 2013 Jun 27.
Gong B, Klein P, Coon M, inventors; CTI Biopharma Inc, assignee. Tricyclic fused xanthine compounds and their uses. US 2002/0103211 A1 (Patent) 2002 Aug 01.
Draijer R, Van Den Born B-JH, inventor; Unilever BCS US Inc, assignee. Theobromine for increasing HDL-cholesterol. US 2013/0116221 A1 (Patent) 2013 May 09.
Hatley RJD, Mason AM, Pinto IL, inventors; GlaxoSmithKline LLC, assignee. Xanthine derivatives as selective HM74A agonists. EP 2272848 (Patent) 2011 Jan 12.
Romanenko MI, Ivanchenko DH, Priimenko BO, Samura BA, inventors; Romanenko MI, Ivanchenko DH, Priimenko BO, Samura BA, applicants. 1-[7-(2-hydroxyethyl-1)-3-methylxanthine-8-yl]piperazine chloride, exhibiting hypotensive, stimulating respiration, diuretic and anti-aggregate action. UA 115953 (Patent) 2018 Jan 10. Ukranian.
State Pharmacopoeia of Ukraine. 2nd ed. Kharkiv: Naukovo-ekspertnyi farmakopeinyi tsentr; 2015.
Downloads
Published
How to Cite
Issue
Section
License
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
